IPP Bureau
AstraZeneca expands its portfolio by bringing rare disease therapy for patients in India
By IPP Bureau - March 01, 2023
Receives regulatory approval for its molecule ‘Selumetinib’ in India
NATCO launches generic Pomalidomide Capsules in Canada
By IPP Bureau - March 01, 2023
Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules
Alembic gets USFDA final approval for ANDA Docetaxel Injection
By IPP Bureau - March 01, 2023
LifeSigns launches smart ward with wireless patient monitoring technology
By IPP Bureau - March 01, 2023
Amala Hospital partners with LifeSigns to provide revolutionary technology for the first time in the State
Venus Remedies awarded Saudi GMP approval for all its production facilities in Baddi
By IPP Bureau - February 28, 2023
The company expects the GMP approval from Saudi Food and Drug Authority (SFDA) to soon pave the way for marketing authorizations from the largest market in the GCC region
CarDekho adds Medulance to provide emergency medical services
By IPP Bureau - February 28, 2023
Sanofi reaffirms commitment to rare diseases in India
By IPP Bureau - February 28, 2023
Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India
India hospital network launched to initiate life-saving colon cancer trial
By IPP Bureau - February 28, 2023
Twelve hospitals across India will be part of the network which will support the trial in India
ENHERTU approved in China for patients with HER2 positive metastatic breast cancer treated withantiHER2-based regimens
By IPP Bureau - February 28, 2023
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
Agilent announces cell analysis workflow automation for immuno-oncology, virology, and vaccine development markets
By IPP Bureau - February 27, 2023
New workflow integrates the xCELLigence RTCA HT with the BioTek BioSpa 8 Automated Incubator
AlloVir appoints Derek Adams to Board of Directors
By IPP Bureau - February 27, 2023
Dr. Adams brings more than two decades of experience leading the manufacturing of biologic and gene therapies at all stages of development.
Granules India gets USFDA approval for Losartan Potassium Tablets USP, 25 mg, 50 mg, and 100 mg
By IPP Bureau - February 27, 2023
Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure.
Biliary tract cancer drug Durvalumab approval key opportunity for AstraZeneca in India, says GlobalData
By IPP Bureau - February 27, 2023
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
Porton Advanced and Yinjia Biosciences partner to enhance CDMO technology platform
By IPP Bureau - February 27, 2023
Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.
Strides flagship facility in Bangalore receives USFDA inspection closure
By IPP Bureau - February 25, 2023
